Figures
Abstract
Background
Shugan Jianpi Zhixie therapy (SJZT) has been widely used to treat diarrhea-predominant irritable bowel syndrome (IBS-D), but the results are still controversial. A meta-analysis of randomized, double-blind, placebo-controlled trials was performed to assess the efficacy and tolerability of SJZT for IBS-D.
Methods
The MEDLINE, EMBASE, Cochrane Library, the China National Knowledge Infrastructure database, the Chinese Biomedical Literature database and the Wanfang database were searched up to June 2014 with no language restrictions. Summary estimates, including 95% confidence intervals (CI), were calculated for global symptom improvement, abdominal pain improvement, and Symptom Severity Scale (BSS) score.
Results
Seven trials (N=954) were included. The overall risk of bias assessment was low. SJZT showed significant improvement for global symptom compared to placebo (RR 1.61; 95% CI 1.24, 2.10; P =0.0004; therapeutic gain = 33.0%; number needed to treat (NNT) = 3.0). SJZT was significantly more likely to reduce overall BSS score (SMD –0.67; 95% CI –0.94, –0.40; P < 0.00001) and improve abdominal pain (RR 4.34; 95% CI 2.64, 7.14; P < 0.00001) than placebo. The adverse events of SJZT were no different from those of placebo.
Citation: Xiao Y, Liu Y, Huang S, Sun X, Tang Y, Cheng J, et al. (2015) The Efficacy of Shugan Jianpi Zhixie Therapy for Diarrhea-Predominant Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials. PLoS ONE 10(4): e0122397. https://doi.org/10.1371/journal.pone.0122397
Academic Editor: John Green, University Hospital Llandough, UNITED KINGDOM
Received: October 14, 2014; Accepted: February 20, 2015; Published: April 8, 2015
Copyright: © 2015 Xiao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper.
Funding: This work was supported by the NSFC-Guangdong joint fund (Nos. U1132001), the National Science Foundation of China (Nos. 81173146, 81373707 and 81403447), the State Administration of Traditional Chinese Medicine (Nos. JDZX2012013), the Major State Basic Research Development Program of China (973 Program Nos. 2013CB531700), the Guangdong Provincial Department of Science and Technology and Guangdong Provincial Academy of Traditional Chinese Medicine joint fund (Nos. 2011B032200004 and 2012A032500004), the Guangdong Provincial Department of Science and Technology fund (Nos. 2011B031700018), China Postdoctoral Science Foundation(Nos. 2014M552187), and Administration of Traditional Chinese Medicine of Guangdong Province, China (Nos. 2012KT1145). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Irritable bowel syndrome (IBS) is associated with symptoms of chronic abdominal pain, bloating and disturbed defecation in the absence of any demonstrable biochemical and anatomical abnormality [1]. About 5%-22% of general population is affected by IBS among various countries [2,3]. IBS causes significant reductions in patients’ quality of life and daily activities and involves substantial healthcare costs [4–6].
Although great progress has been made in the understanding of irritable bowel syndrome, conventional treatment remains unsatisfied. A series of systematic reviews of published drug trials were performed by the American College of Gastroenterology Task Force [7]. The quality of evidence for certain antispasmodics was graded as poor, and for tricyclic antidepressants, selective serotonin reuptake inhibitors, non-absorbable antibiotics, and C-2 chloride channel activators as moderate [7]. The trials of 5HT3 antagonists and 5HT4 agonists were of good quality, but it was noteworthy that these drugs were associated with a potential risk of ischemic colitis and cardiovascular events respectively [7].
Due to chronicity and frequency of symptoms, many patients seek alternative treatments such as traditional Chinese medicine (TCM) [8–10]. TCM is characterized by syndrome differentiation. In this regard, “stagnation of liver energy and deficiency of spleen” is considered to be the basic pathogenic factor of diarrhea-predominant IBS (IBS-D) [11]. Relieving the suppressed liver and replenishing the spleen energy for anti-diarrhea (Chinese name in pinyin “Shugan Jianpi Zhixie”) is the most important therapy in the treatment of IBS-D [12]. Tong Xie Yao Fang, an ancient formula with function of Shugan Jianpi Zhixie, has been prescribed by TCM practitioners for a long time in the treatment of IBS-D [13]. There was a systematic review of Tong Xie Yao Fang for IBS reported in 2006 [14]. In the review, twelve studies were included, but none of them were double-blind, placebo-controlled trials. The authors concluded that no definitive conclusions could be drawn due to the poor quality of the primary trials. Recently, increasing numbers of well-designed trials assessing Shugan Jianpi Zhixie therapy (SJZT) for IBS have been published [12,15–21]. However, the current state of evidence of SJZT for IBS-D has so far been unknown. Therefore, we conducted a meta-analysis of randomized, double-blind, placebo-controlled trials to determine whether SJZT is beneficial to patients with IBS-D.
Methods
Search strategy
A literature search was carried out using Medline (1989 to June 2014), EMBASE (1947 to June 2014), Cochrane Library (1993 to June 2014), the China National Knowledge Infrastructure database (1979 to June 2014), the Chinese Biomedical Literature database (1990 to June 2014) and the Wanfang database (1982 to June 2014). The search terms used were (traditional Chinese medicine OR herbal medicine OR herbs OR herbal formula OR Chinese medicinal herb OR Shugan OR Jianpi OR Zhixie) AND (irritable bowel syndrome OR IBS) AND (randomized controlled trial AND (double-blind trial OR placebo-controlled trial)). No limit was placed on language. Manual searches of relevant studies supplemented the electronic searches.
Study selection
Studies meeting the following criteria were included. (i) Patients were diagnosed with IBS-D. (ii) The study was performed as a randomized, double-blind, placebo-controlled, parallel-group trial that compared the efficacy of SJZT vs. placebo. (iii) Outcomes included at least one of the following: global symptom improvement, IBS Symptom Severity Scale (BSS) score and abdominal pain improvement. Global symptom improvement was recorded as primary outcome, and overall BSS score and abdominal pain improvement were recorded as secondary outcome measures.
Data abstraction
Two researchers independently extracted data, including study design, randomization, diagnostic criteria for IBS-D, TCM criteria, sample size, dose and ingredients of each formula in the included studies, treatment duration, primary and secondary outcomes. Data were extracted as intention-to-treat analyses, in which drop-outs were assumed to be treatment failures, wherever trial reporting allowed this. Disagreements were resolved after discussion with other investigators. Assessment of methodological quality was conducted according to the Cochrane Collaboration tool.
Data synthesis and analysis
Summary relative risk (RR) and 95% confidence intervals (CI) were reported for both global symptom improvement and abdominal pain improvement. Standardized mean difference (SMD) and 95% CI were reported for BSS scores. The χ2 test and the inconsistency index statistic (I2) for heterogeneity were conducted [22]. If substantial heterogeneity occurred (I2 >50% or P<0.05), a random effect model was used to calculate the pooled RR [23]. If there was no observed heterogeneity, the pooled RR was computed by using a fixed effect model. A sensitivity analysis was done to investigate potential sources of heterogeneity between studies through omitting one trial in turn. The number needed to treat (NNT) was calculated as the reciprocal of the therapeutic gain. Begg’s test was performed to evaluate publication bias [24]. Review Manager 5.1 and Stata 12.0 were used for analyses.
We calculated the optimal information size (OIS) to provide appropriate sample size for the meta-analysis [25]. To determine the OIS, a 60% control event rate for the chance of not improving symptomatic was presumed for the outcome global symptom improvement and a 25% RR reduction with a power of 80% and a two-sided α value of 0.01[26].
Results
A total of 85 relevant studies were identified by computer search. Of these, three articles were duplicates and 43 articles were excluded on review of abstracts. After further reviewing, seven studies (N = 954) satisfied the inclusion criteria for the meta-analysis (Fig 1). A description of the included trial characteristics can be found in Table 1. The ingredients of herbal formulae were listed in Table 2.
The risk of bias assessment in the trials was summarized in Fig 2. A low risk of bias was found across studies for adequate sequence generation, allocation concealment, blinding of outcome assessment and selective outcome reporting. There were no details about placebo content in Tang et al. study [18]. Bensoussan et al.[15] and Cai et al.[19] studies were rated as high risk for the “incomplete outcome data” item ascribing to lack of intention-to-treat (ITT) analysis.
Primary outcome: global symptom improvement
Among the included studies, six evaluated global symptom improvement [12,15,16–18,20]: of 917 patients, 570 were assigned to the treatment groups, whereas 347 were assigned to the placebo groups. The number of participants included in this meta-analysis was slightly larger than the calculated OIS (917 vs. 794 patients). SJZT showed significant improvement in global symptoms compared to placebo (RR 1.61; 95% CI 1.24, 2.10; P = 0.0004) (Fig 3a). 76.8% of SJZT patients had global improvement over 43.8% of placebo patients (therapeutic gain = 33.0% with NNT = 3.0) (Table 3). The heterogeneity was significant (P = 0.005, I2 = 70.0%). We performed a sensitivity analysis to investigate potential sources of heterogeneity and found that the Leung et al. study may be the main origin of heterogeneity in the meta-analysis [12]. The heterogeneity was small after exclusion of the Leung et al. study (P = 0.25, I2 = 26%). However, the corresponding pooled RR was not conspicuously altered without the Leung et al. study (RR 1.79 95% CI 1.51, 2.12) (Fig 3b). The findings supported the robustness of the analysis. No evidence of asymmetry was identified by funnel plot analysis (Begg’s test P = 0.707) (Fig 4).
(a) Forest plot of primary outcomes, global symptom improvement with weights from random effects analysis. (b) Sensitivity analysis was performed by omitting one study.
RR, relative risk.
Secondary outcomes
Overall BSS score.
Four of seven studies used BSS to assess the severity of IBS symptoms [15,16,18,19]. SJZT reduced the overall BSS score compared with placebo (SMD—0.67; 95% CI—0.94, –0.40; P<0.00001) (Fig 5a). No substantial heterogeneity was found (P = 0.39, I2 = 0.0%). Funnel plot analysis demonstrated no evidence of publication bias (Begg’s test, P = 1.000) (Fig 6).
(a) Forest plot of secondary outcomes, overall BSS score with weights from fixed effects analysis. (b) Forest plot of secondary outcomes, abdominal pain improvement with weights from fixed effects analysis.
RR, relative risk.
Abdominal pain improvement.
Two of the seven studies reported the outcome of abdominal pain improvement [16,17]. SJZT showed significant improvement for abdominal pain compared to placebo (RR 4.34; 95% CI 2.64, 7.14; P<0.00001) (Fig 5b). No observed heterogeneity existed (P = 0.82, I2 = 0.0%).
Two included studies reported daily bowel frequency [12,16], but the data could not be incorporated because Li et al.[16] reported daily bowel frequency with means and SD values, while Leung et al.[12] reported the outcome as medians.
Two trials assessed health-related quality of life—one used the validated Hong Kong Chinese version of the short form 36 (SF-36) [12], while the other used the irritable bowel syndrome quality of life questionnaire (IBS-QOL) [18]. Both studies reported no significant difference in health-related quality of life between the SJZT group and the placebo group. Because of the heterogeneity of instruments, meta-analysis of the quality of life score could not be conducted.
Safety profile and adverse events
Safety profile was evaluated in all the included studies. Four of these reported no adverse effects during SJZT treatment [16,18–20]. Bensoussan et al. reported that two patients in the standard formula group withdrew from the study associated with gastrointestinal discomfort [15]. In Leung et al.’s study, two participants suffered from skin rash and thyroiditis respectively in the treatment group and one participant suffered from facial nerve palsy in the placebo group [12]. Chen et al. reported two cases each of mild nausea and mild pruritus [17]. The adverse events of SJZT were no different from those of placebo.
Discussion
The results from this meta-analysis revealed that SJZT showed significant improvement in global IBS symptoms (RR = 1.61), BSS score (SMD = –0.67), and abdominal pain (RR = 4.34) compared with placebo. No evidence of publication bias was found. Furthermore, the number of patients reporting adverse events of SJZT was similar to that of placebo.
A high placebo response rate exists in IBS patients. A series of meta-analyses showed that the proportion of placebo participants reporting global improvement was almost 40% [27–29], similar to the response effect of placebo in this meta-analysis (43.8%). The clinical benefit of SJZT for global IBS symptoms was significant, with therapeutic gains over placebo of 33.0% and NNT = 3.0. The reported NNT offered by 5-HT3 receptor antagonist was eight [30]. That being said, SJZT seems to be superior to 5-HT3 receptor antagonist for IBS-D. However, randomized, double-blind trials evaluating SJZT compared with 5-HT3 receptor antagonist for IBS-D have not been found in our search.
The pathogenesis of IBS has not been fully clarified. Numerous mechanisms involve in the development of IBS, including inflammation, gut mucosal immunology, disturbed gastrointestinal motility, gut microbes, visceral hypersensitivity, altered serotonin metabolism, and psychosocial distress [31–36]. Evidence for the effectiveness of SJZT for IBS-D was identified in modern pharmacological studies. Experimental data have demonstrated that Chang ji tai granule can relieve diarrhea symptoms, ameliorate the stress state, inhibit bowel motility, and reduce visceral hypersensitivity in rats with IBS-D, possibly by modulating the expression of substance P mRNA in the hypothalamus and colon [37,38]. Chang an yi hao decoction can significantly reduce visceral hypersensitivity and enhance anti-inflammatory activities by decreasing the expression of 5-HT and regulating the levels of anti-inflammatory cytokines in rats with IBS-D [39]. Further studies in vitro and in vivo of herbal formulae need to be conducted to better understand the drug mechanism
There was significant heterogeneity for the primary outcome. We performed a sensitivity analysis and found that the Leung et al. study may be the main origin of heterogeneity [12]. After exclusion of the Leung et al. study, the heterogeneity was effectively decreased while the corresponding pooled RR was not substantially altered. We checked all of the included studies carefully and found that there was difference of selection criteria of patients between Leung et al. study and the other selected studies. In Leung et al. study, diagnosis of IBS was based on Rome II criteria and the diarrhea-predominant type was defined by the author if diarrhea was present for at least 75% of the time during which a patient’s IBS was active [12]. The rigorous inclusion criterion of patients in Leung et al. study may contribute to the heterogeneity. Furthermore, we explored the pattern of herbal formula in Leung et al. study and found that Leung et al. added several herbs with heat-clearing functions based on SJZT, which maybe another important source of heterogeneity. Treatment based on syndrome differentiation is a characteristic of TCM. Of the included seven studies, the information for TCM syndrome classification was taken into consideration only in four studies [12,16,17,19]. For this reason, syndrome classification could be a matter of heterogeneity among the evaluated trials.
The methodological quality of included studies was general high. However, we did identified potential bias in two domains. Details about the chemical properties of placebo were not reported in Tang et al. study [18]. The extremely high response (89.3%) in the SJZT group in Tang et al. study may be related to spontaneous unblinding that the patient is aware of which treatment he or she is taking. The other flaw in the quality of included studies was the lack of ITT analysis, which could lead to incomplete outcome data. A total of 8 patients withdrew from the Bensoussan et al. study [15], of whom three patients were related to ineffective intervention. Cai et al. excluded two patients because of ineffective intervention [19]. Neither of these studies used ITT analysis and both of the studies were graded as high risk in incomplete outcome data. However, we extracted data as ITT analyses, assuming all drop-outs to be treatment failures, which could reduce the risk of attrition bias.
This meta-analysis had several limitations. First, the absolute number of clinical trials and the sample size of included studies were small. It needed to be demonstrated whether the effect size of SJZT would remain the same when applied in future large-scale trials. In the assessment of publication bias, the power of this meta- analysis was modest due to the small number of trials. Thus, there might be the possible existence of publication bias in our analysis. Second, in the included studies, patients in SJZT group were treated for 3 to 16 weeks under controlled conditions. The treatment duration was not long enough to evaluate the long term safety of SJZT for IBS-D. Third, only three of the included seven trials described follow-up evaluation [12,15,16]. Bensoussan et al. reported that, on follow-up 14 weeks after intervention completed, only the individualized formula treatment group maintained improvement rather than the standard formula group [15]. Because of the recurrent and chronic nature of IBS, long-term follow-up trials might yield different results. Therefore, it is necessary to specify the duration of the follow-up period with SJZT treatment. Fourth, discrepancy in formula composition, methods of preparation, and dose was observed between the studies, which may result heterogeneous.
In summary, the meta-analysis suggests that SJZT is more efficacious than placebo in improving global symptoms, BSS score, and abdominal pain for patients with IBS-D. SJZT is safe in short-term trials. However, due to the high clinical heterogeneity and small sample size of the included trials, further standardized preparation, randomized double-blind, multicenter, large-scale trials are required.
Author Contributions
Conceived and designed the experiments: XSZ. Performed the experiments: XMS YT JRC TW FL YXK. Analyzed the data: YX YYL SHH. Contributed reagents/materials/analysis tools: YX YYL SHH. Wrote the paper: XY YYL SHH XSZ. Study supervision: XSZ RL.
References
- 1. Saito YA, Schoenfeld P, Locke GR 3rd (2002) The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 97: 1910–1915. pmid:12190153
- 2. Lovell RM, Ford AC (2012) Global prevalence of, and risk factors for, irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10: 712–721. pmid:22426087
- 3. Grundmann O, Yoon SL (2010) Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol 25: 691–699. pmid:20074154
- 4. El-Serag HB, Olden K, Bjorkman D (2002) Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 16: 1171–1185. pmid:12030961
- 5. Dean BB, Aguilar D, Barghout V, Kahler KH, Frech F, et al. (2005) Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 11(Suppl 1): S17–26.
- 6. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW (1995) Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 109: 1736–1741. pmid:7498636
- 7. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, et al. (2009) An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 104(Suppl 1): S1–35. pmid:19521341
- 8. Hussain Z, Quigley EM (2006) Systematic review: complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 23: 465–471. pmid:16441466
- 9. Liu JP, Yang M, Liu YX, Wei M, Grimsgaard S (2006) Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 25: CD004116. pmid:16437473
- 10. Shi J, Tong Y, Shen JG, Li HX (2008) Effectiveness and safety of herb medicines in the treatment of irritable bowel syndrome: a systematic review. World J Gastroenterol 14: 454–462. pmid:18200670
- 11. Chinese Society of Digestive Diseases and Chinese Association of Chinese Medicine (2010) Consensus on the diagnosis and treatment of functional dyspepsia irritable bowel syndrome by Traditional Chinese Medicine. China J Trad Chin Med Pharm 25:1062–1065.
- 12. Leung WK, Wu JC, Liang SM, Chan LS, Chan FK, et al. (2006) Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo controlled trial. Am J Gastroenterol 101: 1574–1580. pmid:16863563
- 13. Sung JJ, Leung WK, Ching JY, Lao L, Zhang G, et al. (2004) Agreements among traditional Chinese medicine practitioners in the diagnosis and treatment of irritable bowel syndrome. Aliment Pharmacol Ther 20: 1205–1210. pmid:15569124
- 14. Bian Z, Wu T, Liu L, Miao J, Wong H, et al. (2006) Effectiveness of Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J Altern Complement Med 12: 401–407. pmid:16722791
- 15. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, et al. (1998) Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 280: 1585–1589. pmid:9820260
- 16. Li YM, Zhang YN, Cai G, Chen MX (2010) Treatment of diarrhea-predominant irritable bowel syndrome with Chang Ji Tai Granule: A randomized, double-blinded and placebo-controlled trial. Shanghai J Trad Chin Med 44: 33–36.
- 17. Chen DF, Xia Q, Gong M, Liu XL, Jiang YP, et al. (2010) Effects of Tong Xie Ning granule in treatment of diarrhea-predominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled, multicenter study. Chin J Dig 30: 327–330.
- 18.
Tang XD, Li ZH, Li BS, Gao R, Wang FY, et al. (2011) Treatment of diarrhea-predominant irritable bowel syndrome with Chang An Yi Hao decoction: A randomized, double-blinded and placebo-controlled trial. Seventh National Symposium of Rehabilitation Medicine Health Professional Committee, Chinese Association of Integrative Medicine 1–9.
- 19. Cai LJ, Lv B, Meng LN, Ma LJ, Fan YH (2013) Treatment of diarrhea-predominant irritable bowel syndrome with Shu Gan Jian Pi Wen Shen decoction: A randomized controlled trial. Chin Arch Trad Chin Med 5: 1097–1099.
- 20. Li YM, Lin J, Cai G, Chen MX (2014) A randomized, double-blinded and placebo-controlled research on Chang Ji Tai combined with percutaneous acupoint stimulation of in treatment of diarrhea-predominant irritable bowel syndrome. Chin J Integr Trad West Med Dig 22: 1–4.
- 21. Xiao HT, Zhong L, Tsang SW, Lin ZS, Bian ZX (2015) Traditional Chinese Medicine Formulas for Irritable Bowel Syndrome: From Ancent Wisdoms to Scientific Understandings. Am J Chin Med 11: 1–23.
- 22. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560. pmid:12958120
- 23. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188. pmid:3802833
- 24. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–10101. pmid:7786990
- 25. Pogue JM, Yusuf S (1997) Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials 18: 580–593. pmid:9408720
- 26. Alonso-Coello P, Zhou Q, Martinez-Zapata MJ, Mills E, Heels-Ansdell D, et al. (2006) Meta-analysis of flavonoids for the treatment of haemorrhoids. Br J Surg 93:909–920. pmid:16736537
- 27. Ford AC, Moayyedi P (2010) Meta-analysis: factors affecting placebo response rate in irritable bowel syndrome. Aliment Pharmacol Ther 32: 144–158. pmid:20412064
- 28. Dorn SD, Kaptchuk TJ, Park JB, Nguyen LT, Canenguez K, et al. (2007) A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol Motil 19: 630–637. pmid:17640177
- 29. Sands BE (2009) The placebo response rate in irritable bowel syndrome and inflammatory bowel disease. Dig Dis 27(Suppl 1): 68–75. pmid:20203499
- 30. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, et al. (2009) Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 104: 1831–1843. pmid:19471254
- 31. Chang JY, Talley NJ (2010) Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment. Trends Pharmacol Sci 31: 326–334. pmid:20554042
- 32. Rapps N, van Oudenhove L, Enck P, Aziz Q (2008) Brain imaging of visceral functions in healthy volunteers and IBS patients. J Psychosom Res 64: 599–604. pmid:18501260
- 33. Ringel Y, Maharshak N (2013) Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 305: G529–541. pmid:23886861
- 34. Törnblom H, Lindberg G, Nyberg B, Veress B (2002) Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 123: 1972–1979. pmid:12454854
- 35. Karantanos T, Markoutsaki T, Gazouli M, Anagnou NP, Karamanolis DG (2010) Current insights in to the pathophysiology of irritable bowel syndrome. Gut Pathog 2: 3. pmid:20465787
- 36. Chitkara DK, van Tilburg MA, Blois-Martin N, Whitehead WE (2008) Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am J Gastroenterol 103: 765–774. pmid:18177446
- 37. Cong J, Cai G, Lin J,Zhang ZL (2013) Effect of Chang Ji Tai decoction on expression of substance P mRNA in the colonic mucosa and hypothalamus of rats with diarrhea-predominant irritable bowel syndrome. World Chin J Digest 21: 1234–1238.
- 38. Lin J, Li YM, Li L,Cai G (2010) Effect of Chang Ji Tai on voltage-gated sodium channel Nav1.8 and nerve growth factor in the rats with visceral hypersensitivity. Chin J Integr Trad West Med Dig18:355–358.
- 39. Lin M, Tang XD, Wang FY, Bian ZX, Yang JQ (2012) Effect of Chang An Yi Hao decoction and placebo on TNF-α and IL-10 in rats with irritable bowel syndrome of diarrhea pattern. Shanghai J TCM 46:82–84.